PUBLICATIONS AND PresentationS

Source plasma (SP) is the primary starting material for 87% of plasma-derived medicinal products globally. Plasmavigilance is a program designed to collect, analyze, and monitor donor adverse events (AEs) across the SP collection industry.

In the coming decade European countries will see an increased need for plasma-derived medicines to treat their patients for a range of rare diseases and critical medical conditions. While demand for blood components for transfusion remains relatively stable, a European Commission survey (2014) shows that demand for plasma derivatives is increasing by some 6% per year.

Plasma-derived therapies are therapies derived from human plasma. They are manufactured using a fractionation process where the relevant proteins in plasma are separated out.

The online event entitled “The revision of the EU Blood Directive: How to enhance plasma collection by getting more donors via increased regulatory efficiency?”, organized and hosted by Member of the European Parliament (MEP) Sirpa Pietikäinen took place on April 21, 2021.